In this way, the depth and dimensionality of immune profiling in HPV-related cervical, vulvar, and penile cancer will be greatly improved and may lead to more accurate predictors of clinical response for patients receiving PD-1/PD-L1 inhibitors as well as other novel immunotherapeutic agents. This evidence concerns the gene CD274 and penile cancer.